公开(公告)号：US20240058344A1

公开(公告)日：2024-02-22

申请号：US18268102

申请日：2021-12-17

申请人： Cornell University

发明人： Adam Orr ,  Anna Orr

IPC分类号： A61K31/519 ,  A61K31/18 ,  A61K31/343 ,  A61K31/385 ,  A61K31/426 ,  A61K31/498 ,  A61K31/517 ,  A61P25/28 ,  A61P35/00

CPC分类号： A61K31/519 ,  A61K31/18 ,  A61K31/343 ,  A61K31/385 ,  A61K31/426 ,  A61K31/498 ,  A61K31/517 ,  A61P25/28 ,  A61P35/00

摘要： Disclosed herein are methods of treating or preventing neurodegenerative disease, neuronal damage, neuroinflammation, or cancer using suppressors of electron leak.

公开(公告)号：US20240050428A1

公开(公告)日：2024-02-15

申请号：US18248035

申请日：2021-10-07

申请人： Cullgen (Shanghai), Inc.

发明人： Jing LIU ,  Michael Bruno PLEWE ,  Jialiang WANG ,  Xiaoran HAN ,  Liqun CHEN ,  Ting YANG ,  Chengwei ZHANG

IPC分类号： A61K31/498 ,  A61K31/4545 ,  A61K31/454 ,  A61K31/5025 ,  A61K31/497 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K31/498 ,  A61K31/4545 ,  A61K31/454 ,  A61K31/5025 ,  A61K31/497 ,  A61K45/06 ,  A61P35/00

摘要： This disclosure relates to GSPT1 degrader compounds (e.g. small molecule compounds), compositions comprising one or more of the compounds, and to methods of use the compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such compounds.

公开(公告)号：US20240016948A1

公开(公告)日：2024-01-18

申请号：US18128828

申请日：2023-03-30

申请人： Sunstate Biosciences, LLC

发明人： Changjun Yu

IPC分类号： A61K47/68 ,  A61K47/64 ,  A61P35/00 ,  A61K31/136 ,  A61K31/337 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/498 ,  A61K31/519 ,  A61K31/704

CPC分类号： A61K47/6803 ,  A61K47/643 ,  A61K47/6809 ,  A61K47/6835 ,  A61P35/00 ,  A61K31/136 ,  A61K31/704 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/498 ,  A61K31/519 ,  A61K31/337

摘要： The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and/or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition.

公开(公告)号：US11857521B1

公开(公告)日：2024-01-02

申请号：US17854360

申请日：2022-06-30

申请人： Joong Ho Moon ,  Michelle Miranda

发明人： Joong Ho Moon ,  Michelle Miranda

IPC分类号： A61K8/43 ,  A61K31/155 ,  C07D295/215 ,  A61K31/17 ,  C07C279/12 ,  A61K31/496 ,  A61K31/498 ,  A61K31/47 ,  A61K31/277 ,  A61K31/5377 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/133 ,  A61P31/06 ,  C08G65/00 ,  C08G71/02 ,  A61P31/04

CPC分类号： A61K31/17 ,  A61K31/133 ,  A61K31/277 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/496 ,  A61K31/498 ,  A61K31/4965 ,  A61K31/5377 ,  A61P31/06 ,  C07C279/12 ,  C07D295/215 ,  C08G65/00 ,  C08G71/02 ,  C07C2601/16

摘要： The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.

公开(公告)号：US20230381196A1

公开(公告)日：2023-11-30

申请号：US18026416

申请日：2021-09-17

申请人： AYALA PHARMACEUTICALS INC.

发明人： Dana GELBAUM ,  Jeffrey KAUFMAN ,  Joel KAYE

IPC分类号： A61K31/5513 ,  A61K31/506 ,  A61K31/203 ,  A61K31/498 ,  A61K31/519 ,  A61P35/00

CPC分类号： A61K31/5513 ,  A61K31/506 ,  A61K31/203 ,  A61K31/498 ,  A61K31/519 ,  A61P35/00

摘要： The present invention provides methods of treating or suppressing Adenoid Cystic Carcinoma (ACC) or inhibiting ACC tumor growth in subjects by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (III) or prodrugs thereof.

公开(公告)号：US20230372338A1

公开(公告)日：2023-11-23

申请号：US18346029

申请日：2023-06-30

申请人： Foundation Medicine, Inc.

发明人： Siraj Mahamed ALI ,  Matthew J. HAWRYLUK ,  Jie HE ,  Doron LIPSON ,  Vincent A. MILLER ,  Jeffrey S. ROSS ,  Philip James STEPHENS

IPC分类号： A61K31/5025 ,  C12N9/12 ,  A61K31/4412 ,  A61K45/06 ,  A61K31/47 ,  A61K31/435 ,  A61K31/506 ,  A61K31/519 ,  A61K31/4439 ,  A61K31/53 ,  A61K31/404 ,  A61K31/5383 ,  A61K31/498 ,  A61K31/496 ,  A61K31/517 ,  C12Q1/6886 ,  A61K31/553 ,  C07K14/705 ,  C07K14/71 ,  C07K16/40 ,  C12N15/113 ,  C12Q1/6883 ,  G01N33/573

CPC分类号： A61K31/5025 ,  C12N9/12 ,  A61K31/4412 ,  A61K45/06 ,  A61K31/47 ,  A61K31/435 ,  A61K31/506 ,  A61K31/519 ,  A61K31/4439 ,  A61K31/53 ,  A61K31/404 ,  A61K31/5383 ,  A61K31/498 ,  A61K31/496 ,  A61K31/517 ,  C12Q1/6886 ,  A61K31/553 ,  C07K14/705 ,  C07K14/71 ,  C12Y207/10001 ,  C07K16/40 ,  C12N15/1137 ,  C12Q1/6883 ,  G01N33/573 ,  C12Q2600/156 ,  C07K2319/00 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/14 ,  C12Q2600/158 ,  G01N2333/912 ,  G01N2500/04

摘要： Methods and compositions for treating cholangiocarcinoma.

公开(公告)号：US20230364057A1

公开(公告)日：2023-11-16

申请号：US18139681

申请日：2023-04-26

申请人： THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES ,  UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.

发明人： Fenfei LENG ,  Eddy ALFONSO ,  Zifang DENG ,  Adel NEFZI ,  Kyle ROHDE

IPC分类号： A61K31/404 ,  A61K31/196 ,  A61K31/5377 ,  A61K31/427 ,  A61K31/519 ,  A61K31/428 ,  A61K31/429 ,  A61K31/41 ,  A61K31/433 ,  A61K31/513 ,  A61K31/366 ,  A61K31/443 ,  A61K31/635 ,  A61K31/496 ,  A61K31/24 ,  A61K31/164 ,  A61K31/426 ,  A61K31/48 ,  A61K31/4155 ,  A61K31/4184 ,  A61K31/381 ,  A61K31/498 ,  A61K31/195 ,  A61K31/352 ,  A61K31/7076 ,  A61K31/4178 ,  A61K31/192 ,  A61K31/473 ,  A61K31/517 ,  A61K31/4745 ,  A61K31/502 ,  A61K31/345 ,  A61K31/422 ,  A61K31/4436 ,  A61K31/4365 ,  A61K31/4439 ,  A61K31/197 ,  A61K31/137 ,  A61K31/45 ,  A61K31/15 ,  A61K31/4402 ,  A61K31/136 ,  A61K31/4245 ,  A61K31/351 ,  A61K31/437 ,  A61K31/47 ,  A61K31/122 ,  A61K31/365 ,  A61K31/438 ,  A61K31/436 ,  A61K31/515 ,  A61K31/53 ,  A61K31/357 ,  A61K31/4162 ,  A61K31/538 ,  A61P31/04

CPC分类号： A61K31/404 ,  A61K31/122 ,  A61K31/136 ,  A61K31/137 ,  A61K31/15 ,  A61K31/164 ,  A61K31/192 ,  A61K31/195 ,  A61K31/196 ,  A61K31/197 ,  A61K31/24 ,  A61K31/345 ,  A61K31/351 ,  A61K31/352 ,  A61K31/357 ,  A61K31/365 ,  A61K31/366 ,  A61K31/381 ,  A61K31/41 ,  A61K31/4155 ,  A61K31/4162 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/429 ,  A61K31/433 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4402 ,  A61K31/443 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/45 ,  A61K31/47 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/48 ,  A61K31/496 ,  A61K31/498 ,  A61K31/502 ,  A61K31/513 ,  A61K31/515 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/635 ,  A61K31/7076 ,  A61P31/04

摘要： The subject invention provides fluorophore-quencher nucleic acid molecules comprising relaxed or supercoiled DNA molecules, and their use in rapid and efficient high-throughput screening (HTS) assays to screen and identify compounds that inhibit DNA gyrases. These compounds can be used as antibiotics for treating bacterial infections, especially, multidrug resistant bacterial infections.

公开(公告)号：US20230321087A1

公开(公告)日：2023-10-12

申请号：US18044232

申请日：2021-09-13

申请人： JANSSEN PHARMACEUTICA NV

发明人： Ademi Elena SANTIAGO-WALKER ,  Christopher H. MOY

IPC分类号： A61K31/498 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K31/498 ,  A61K39/3955 ,  A61P35/00

摘要： Described herein are methods of treating cancer comprising administering a fibroblast growth factor receptor (FGFR) inhibitor in combination with an epidermal growth factor receptor (EGFR) inhibitor, a Cyclin D1 (CCND1) inhibitor or a BRAF inhibitor to a patient in need of cancer treatment, wherein the patient harbors at least one FGFR2 genetic alteration or FGFR3 genetic alteration and at least one EGFR, CCND1 or BRAF genetic alteration, respectively. Also described herein are methods of predicting duration of progression-free survival (PFS) or overall survival (OS) in a patient, in particular a human patient, having cancer, in particular in a patient on treatment with an FGFR inhibitor, the method comprising evaluating a biological sample from the patient for the presence of at least one FGFR2 genetic alteration or FGFR3 genetic alteration and at least one EGFR, CCND1, or BRAF genetic alteration, wherein the presence of at least one FGFR2 genetic alteration or FGFR3 genetic alteration and at least one EGFR, CCND1, or BRAF genetic alteration indicates a shorter duration of PFS or a shorter duration of OS, relative to a patient, in particular a human patient, having cancer who does not harbor at least one EGFR, CCND1, or BRAF genetic alteration, respectively, or relative to a patient, in particular a human patient, having cancer who does not harbor at least one FGFR2 genetic alteration or FGFR3 genetic alteration and at least one EGFR, CCND1, or BRAF genetic alteration, respectively. Additionally, described herein are methods of improving PFS or OS in a patient with cancer relative to a patient with cancer who was not receiving treatment with an FGFR inhibitor in combination with an EGFR inhibitor, a CCND1 inhibitor or a BRAF inhibitor, said method comprising providing to said patient an FGFR inhibitor in combination with an EGFR inhibitor, a CCND1 inhibitor or a BRAF inhibitor, wherein said patient harbors at least one FGFR2 genetic alteration or FGFR3 genetic alteration and at least one EGFR, CCND1, or BRAF genetic alteration, respectively.

公开(公告)号：US20230321086A1

公开(公告)日：2023-10-12

申请号：US18022642

申请日：2021-11-19

申请人： Universiy of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Beibei Chen ,  Toren Finkel ,  Yuan Liu

IPC分类号： A61K31/498 ,  A61K31/5377 ,  A61K31/4985 ,  A61K31/513 ,  A61K31/501 ,  A61K31/538

CPC分类号： A61K31/498 ,  A61K31/5377 ,  A61K31/4985 ,  A61K31/513 ,  A61K31/501 ,  A61K31/538

摘要： This document provides compounds that are inhibitors of NAMPT activity, as well as the methods of using such compounds for treating diseases and conditions such as cancer, inflammatory conditions, autoimmune conditions, and conditions characterized by acute or sub-acute neuronal injury.

公开(公告)号：US20230310392A1

公开(公告)日：2023-10-05

申请号：US18301510

申请日：2023-04-17

申请人： Lenz Therapeutics, Inc.

发明人： Gerald Horn

IPC分类号： A61K31/439 ,  A61K31/498 ,  A61K9/00 ,  A61K47/26 ,  A61K47/38 ,  A61P27/02

CPC分类号： A61K31/439 ,  A61K9/0048 ,  A61K31/498 ,  A61K47/26 ,  A61K47/38 ,  A61P27/02

摘要： The present invention is directed to compositions for and methods for the treatment of presbyopia, irregular astigmatism, and/or refractive error comprising from about 0.1% to about 4.0% w/w of a muscarinic agonist and from about 0.07% to about 0.15% w/w brimonidine.